Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
Cancer Medicine|July 27, 2021
Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology eraKazuyuki Numakura, Yumin Muto, Sei Naito, et al.
Cancer Medicine|October 6, 2022
Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective studyRyuta Sobu, Kazuyuki Numakura, Sei Naito, et al.
Human Molecular Genetics|June 28, 2022
Different risk genes contribute to clear cell and non-clear cell renal cell carcinoma in 1532 Japanese patients and 5996 controlsYuya Sekine, Yusuke Iwasaki, Tomomi Aoi, et al.
International Journal of Clinical Oncology|May 13, 2020
Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutesKazuyuki Numakura, Mizuki Kobayashi, Shingo Hatakeyama, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 4, 2025
Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter StudyKai Ozaki, Hayato Yamamoto, Yuya Sekine, et al.
Scientific Reports|July 18, 2025
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinomaTakafumi Fukushima, Kazuyuki Numakura, Masanao Shinohara, et al.
Cancer Science|December 8, 2011
Genomic profiling of renal cell carcinoma in patients with end-stage renal diseaseToru Inoue, Keiko Matsuura, Taichiro Yoshimoto, et al.
Urology|June 14, 2022
Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCGTakamitsu Inoue, Makito Miyake, Nobutaka Nishimura, et al.
Cancer Science|December 29, 2019
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 30, 2023
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart reviewJunji Yonese, Nobuyuki Hinata, Satoru Masui, et al.
Pageof 19